EU regulator promises speedy review of potential COVID-19 drug remdesivir

The European health regulator said on Friday its panel would conduct a speedy review of the potential COVID-19 drug, remdesivir.

The European Medicines Agency said its human medicines committee's (CHMP) timeline to assess the drug would be "reduced to the absolute minimum," adding that Gilead Sciences hadn't submitted an application for the treatment yet. (https://bit.ly/2ZPh6HA)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)